Financials

  • Market Capitalization 2.64 B
  • Employee 99
  • Founded 2018
  • CEO Florian Brand
  • Website www.ataibeckley.com
  • Headquarter Delaware, United States
  • FIGI BBG0107FR3K9
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-1.41
Price to sales ratio
226.59

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
1767
BEAM
Beam Therapeutics Inc. - Common Stock
26.49 USD+1.81%+1.22%-23.02%+38.91%2.73 B USD
1790
KOD
Kodiak Sciences Inc - Common Stock
42.50 USD+6.22%+2.04%+11.46%+576.75%2.66 B USD
1812
IMNM
Immunome, Inc. - Common Stock
23.08 USD-0.13%+4.29%+11.77%+125.17%2.61 B USD
1813
TRVI
Trevi Therapeutics, Inc. - Common Stock
18.40 USD+1.71%+5.99%-1.02%+147.64%2.61 B USD

Frequently asked questions about AtaiBeckley Inc. - Common Stock

What is the AtaiBeckley Inc. - Common Stock stock price today?

The current price of AtaiBeckley Inc. - Common Stock (ATAI) is 7.18. Over the past 24 hours, the stock has changed by 0.00%. Follow the ATAI chart for real-time price dynamics.

What is the stock ticker of AtaiBeckley Inc. - Common Stock?

AtaiBeckley Inc. - Common Stock trades under the ticker ATAI. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is AtaiBeckley Inc. - Common Stock stock going up?

ATAI has changed by +0.14% over the last week, +37.81% over the last month, and +81.77% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of AtaiBeckley Inc. - Common Stock?

AtaiBeckley Inc. - Common Stock currently has a market capitalization of 2.64 B. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were AtaiBeckley Inc. - Common Stock earnings last quarter?

Last quarter, AtaiBeckley Inc. - Common Stock reported earnings of -0.08 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was AtaiBeckley Inc. - Common Stock revenue for the last quarter?

AtaiBeckley Inc. - Common Stock reported quarterly revenue of 954 K. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was AtaiBeckley Inc. - Common Stock net income for the last quarter?

AtaiBeckley Inc. - Common Stock reported net income of -29.78 M for the last quarter. The previous quarter showed -661.71 M, which means net income changed by +95.50%.

How many employees does AtaiBeckley Inc. - Common Stock have?

As of the latest available data, AtaiBeckley Inc. - Common Stock has 99 employees. Workforce size can provide additional context about the company's scale and operations.

What is AtaiBeckley Inc. - Common Stock EBITDA?

AtaiBeckley Inc. - Common Stock EBITDA is -30.73 M, and its EBITDA margin is -3 221.59%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy AtaiBeckley Inc. - Common Stock stock?

You can buy AtaiBeckley Inc. - Common Stock (ATAI) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in AtaiBeckley Inc. - Common Stock stock?

Investing in AtaiBeckley Inc. - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the ATAI chart and related analysis on metatrader.com as part of your research.

AtaiBeckley Inc. - Common Stock

atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany. The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine. In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff. Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways.

News